Medindia

X

Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2009

Friday, October 30, 2009 General News J E 4
Advertisement
Cardiometabolic and genetic testing complement advanced cholesterol profile

BIRMINGHAM, Ala., Oct. 29 -- Atherotech, Inc., a cardiodiagnostic company, announced it will exhibit its VAP® Cholesterol Test at the American Heart Association Scientific Sessions 2009. The annual meeting takes place November 14-18 at the Orange County Convention Center in Orlando, Fla.

Representatives for Atherotech will be available during regular exhibit hours on November 15, 16 and 17  to discuss the VAP Cholesterol Test in booth No. 1814, and the VAP Test will be provided via blood draw to qualified attendees. Because LDL is directly measured, fasting is not required. Test results will be returned via mail after the conference.

The VAP (Vertical Auto Profile) Test, an expanded cholesterol profile that directly measures the content of all lipids, identifies a far greater number of people at risk for heart disease than standard cholesterol tests.

"Attendees will learn how we're complementing our VAP Test offering with the addition of cardiometabolic and genetic testing, giving physicians and cardiology practices a single source for multiple test panels," said Atherotech Chief Medical Officer Michael E. Cobble, M.D.

The VAP Test reports 20 separate components of cholesterol, and unlike other lipid profiles, it directly measures all three lipoprotein parameters — LDL, non-HDL and apoB — considered necessary by the expert consensus guidelines issued by the American Diabetes Association and American College of Cardiology. The VAP Test is also the only single cholesterol test that routinely reports apoAI, apoB and the apoB/apoAI ratio.

Atherotech continues to grow its cardiodiagnostic business. The company recently added the PLAC Test for identification of increased heart attack and stroke risk and the cystatin C test as an early, sensitive marker for chronic kidney disease. Unlike creatinine, cystatin C is not affected by muscle mass, gender, age or race. Cystatin C has been shown to be a superior marker of kidney function compared to creatinine, according to the National Kidney Foundation.

Other cardiometabolic and genetic tests now available through Atherotech include C-Reactive Protein (hsCRP), apoE genotype, NT-proBNP, creatinine, creatine kinase (CK), HbA1c, insulin, TSH, ALT, AST, urea nitrogen (BUN), glucose, vitamin D and homocysteine. Cardiometabolic test panels can be ordered individually or bundled as part of a custom risk profile that also includes the advanced VAP Cholesterol Test.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease — or who are already taking cholesterol-lowering medication — are candidates for the VAP Test.

The VAP Test is available nationwide. For more information call 877.901.8510 or visit www.thevaptest.com.

About Atherotech, Inc.

Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.thevaptest.com.

SOURCE Atherotech, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
PRO-DEX, INC. Announces Fiscal First Quarter 2010 ...
S
1.9 Million Drivers Have Fatigue-Related Car Crash...